ArticleBMC nephrology2026
Ultrasound-assisted diagnosis and ultrasound-guided radiofrequency ablation of renal cell carcinoma in a patient with autosomal dominant polycystic kidney disease: a case report with two-year follow-up.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cystic enlargement and an increased risk of renal cell carcinoma. Early diagnosis and treatment are often hindered by severe distortion of renal architecture and by the limitations of contrast-enhanced computed tomography or magnetic resonance imaging in patients with impaired renal function. Contrast-enhanced ultrasound offers a nephrotoxic-free alternative for lesion characterization, treatment planning, and post-ablation monitoring. CASE PRESENTATION: A 44-year-old woman was referred for evaluation of newly detected autosomal dominant polycystic kidney disease (ADPKD). Admission ultrasound showed markedly enlarged cystic kidneys and a 2.2-cm isoechoic lesion in the left kidney that could not be characterized due to the distorted anatomy. To avoid repeat contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI), contrast-enhanced ultrasound demonstrated heterogeneous intralesional enhancement with relatively rapid washout, and positron emission tomography-computed tomography (PET-CT) showed focal hypermetabolism. After cessation of dual antiplatelet therapy and correction of anemia, ultrasound-guided core biopsy confirmed renal cell carcinoma. The patient underwent percutaneous radiofrequency ablation, and post-procedural contrast-enhanced ultrasound (CEUS) showed no residual enhancement. Follow-up imaging at 6 and 24 months revealed no recurrence, and renal function remained stable.
conclusionsThis case highlights the role of CEUS in detecting and characterizing renal tumors in ADPKD, and its utility in post-ablation surveillance. Ultrasound-guided radiofrequency ablation (RFA) is a safe, nephron-sparing treatment for localized RCC in ADPKD patients, especially when traditional contrast-enhanced imaging is limited by renal dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.